Home
Submit New Manuscript
Manuscripts in Draft (
0
)
Pending Revisions (
0
)
Manuscripts in Review (
0
)
Accepted Manuscripts (
0
)
Rejected Manuscripts (
0
)
Manuscripts in Review (
0
)
Co-Author History (
0
)
Home
Pending Review (
0
)
Expired/Declined (
0
)
Accepted Manuscripts (
0
)
Rejected Manuscripts (
0
)
Menu
Disease
A-Z
Health Topics
Alternative Medicine
Developmental Pediatrics
General Pediatrics
Genetics
Immunodeficiencies
Infectious Diseases
Laboratory Medicine
Neonatology
Nutrition
Pediatric Cardiology
View all Topics
Featured Articles
Skin allergies
Anal itching
Anaphylaxis
Cushing's syndrome
Diabetic ketoacidosis
Anal fissure
Kids Corner
Health and Knowledge with fun.
Drugs &
Calculators
Medical Calculators
Drug Calculators
Genetic Calculators
Growth Calculators
View all Calcualtors
Drug Index
ACE inhibitor
Alkylating agents
Allergies
View all Drugs
Poisoning Center
Aluminum phosphide
Anti-histaminics
Antidepressants
View all Drugs
Medical Eqipments
Monitors
Pumps
Incubators
View all Equipments
Diagnostic Aid
Get your diffrential
diagnosis.
Consult
& Posts
Ask a Doctor
Diagnostic Dilemma
Question of the Week
Pediatric Blogs
Spot Diagnosis
Grand Rounds
Pedi Poll
Pediatric
Journal
Current Issue
All Issues
Advance Access
About the Journal
Submit Article
Books
& Apps
Book Store
Pediatric Oncall
Medical Calculators
Vaccine Reminder
Pediatric Oncall Journal
Drug Center
Parenting
CME &
Videos
Upcoming Conferences
Conference Abstracts
MCQs
Videos
Vaccine
Reminder
Sign In
Pediatric News
Novel single dose treatment for Influenza - FDA approves Xofluza (Baloxavir marboxil)
Reepa Agrawal
More..
02 Nov, 2018
After nearly two decades, a new antiviral drug - Baloxavir marboxil (Xofluza) is now approved by FDA for treatment of influenza. It is a single dose therapy approved for uncomplicated acute influenza in patients 12 years of age and above within 48 hours of onset of symptoms. It is also useful in treatment of patients with oseltamivir resistant influenza.
Baloxavir marboxil is a selective inhibitor of influenza cap- dependent endonuclease. It prevents replication by inhibiting the process known as 'cap snatching' which is performed by cap-dependent endonuclease of PA subunit.
It is administered orally in the dose of 40 mg for patients weighing <80 kg or 80 mg for above 80kgs weight.
This molecule was studied in a phase 3 trial, CAPSTONE -1 and was compared with placebo and oseltamivir (75 mg twice daily for five days), in otherwise healthy people with the flu. It significantly reduced the duration of flu symptoms compared to placebo, and demonstrated similar efficacy compared to oseltamivir
In clinical trials, it was safe and well-tolerated with a side effect profile similar to placebo. Adverse effects seen in about 1% of patients were diarrhea, bronchitis, nasopharyngitis, nausea, sinusitis, headache, vomiting and dizziness.
Baloxavir marboxil is developed by Shinogi Co., a Japanese pharmaceutical company and Roche AG.
It appears to be promising as a single dose for uncomplicated acute influenza but further research is warranted for its use in complicated influenza.
×
Author Information
Reepa Agrawal
DCH (Pediatrics)
News Date :
11/02/2018
Novel single dose treatment for Influenza - FDA approves Xofluza (Baloxavir marboxil)
/pediatric-news/novel-single-dose-treatment-for-influenza-fda-approves-xofluza-baloxavir-marboxil/1
11/02/2018
Ask a Doctor
Book Store
Infection in Children - Part 3
Order Now
Recommended for you
Bleeding from Rectum
Renal Tubular Acidosis (RTA)
Scurvy (Vitamin C Deficiency) - Imaging
Videos
Effective Management for Recurrent Worm Infections in a Family
Children with HIV progressing to adulthood- Transition Challenges
Special Conditions in TB
View All
Spot Diagnosis
Axillary swelling after vaccine
Unusual case of cervical swelling
Neonatal lupus erythematosus - a cause to remember in newborn dermatosis
View All
Pediatric Oncall Journal
Letter To Editor(Viewers Choice)
When a child refuses to walk
Images In Clinical Practice
T-cell lymphoblastic lymphoma: an imaging finding
Grand Rounds
Asymptomatic Congenital Parvovirus infection in a neonate born to an asymptomatic mother with Parvovirus infection in the third trimester - Management issues
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
X
Sign In
Disease A-Z
Health Topics
Alternative Medicine
Developmental Pediatrics
General Pediatrics
Genetics
Immunodeficiencies
Infectious Diseases
Laboratory Medicine
Neonatology
Nutrition
Pediatric Cardiology
View all topics
Featured Articles
Skin allergies
Anal itching
Anaphylaxis
Cushing's syndrome
Diabetic ketoacidosis
Anal fissure
Kids Corner
Drugs & Calculators
Medical Calculators
Drug Calculators
Genetic Calculators
Growth Calculators
View all Calculators
Drug Index
ACE inhibitor
Alkylating agents
Allergies
View all Drugs
Poisoning Center
Aluminum phosphide
Anti-histaminics
Antidepressants
View all Drugs
Medical Eqipments
Monitors
Pumps
Incubators
View all Eqipments
Diagnostic Aid
Consult & Posts
Ask a Doctor
Diagnostic Dilemma
Question of the Week
Pediatric Blogs
Spot Diagnosis
Grand Rounds
Pedi Poll
Pediatric Oncall Journal
Current Issue
All Issues
Advance Access
About the Journal
Submit Article
Books & Apps
Book Store
Pediatric Oncall
Medical Calculators
Vaccine Reminder
Pediatric Oncall Journal
Drug Center
Parenting
CME & Videos
Upcoming Conferences
Conference Abstracts
MCQs
Videos
Vaccine Reminder
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0